Header Logo

Connection

Frederick Raal to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications Frederick Raal has written about Cardiovascular Diseases.
Frederick Raal
Connection Strength
10,431
Cardiovascular Diseases
  1. Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor. S Afr Med J. 2023 Nov 06; 113(11):35-40.
    View in: PubMed
    Score: 0,698
  2. Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 07 11; 82(2):171-181.
    View in: PubMed
    Score: 0,683
  3. Premature cardiovascular deaths. S Afr Med J. 2023 06 21; 113(7):6-7.
    View in: PubMed
    Score: 0,680
  4. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. S Afr Med J. 2022 05 31; 112(6):426-432.
    View in: PubMed
    Score: 0,632
  5. Never too old to benefit from lipid-lowering treatment. Lancet. 2020 11 21; 396(10263):1608-1609.
    View in: PubMed
    Score: 0,568
  6. New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors. S Afr Med J. 2020 Oct 28; 110(11):13126.
    View in: PubMed
    Score: 0,566
  7. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Cardiovasc J Afr. 2020 Sep/Oct; 31(5):245-251.
    View in: PubMed
    Score: 0,560
  8. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther. 2019 02; 33(1):69-76.
    View in: PubMed
    Score: 0,502
  9. Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther. 2016 Feb; 30(1):101-8.
    View in: PubMed
    Score: 0,408
  10. Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Curr Cardiol Rep. 2015 Nov; 17(11):104.
    View in: PubMed
    Score: 0,401
  11. New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am. 2014 Dec; 43(4):1007-33.
    View in: PubMed
    Score: 0,376
  12. What matters most in pediatric familial hypercholesterolemia, genotype or phenotype? J Lipid Res. 2014 May; 55(5):793-5.
    View in: PubMed
    Score: 0,359
  13. The cardiovascular health of the nation - should we be advocating a low-carbohydrate, high-fat diet? S Afr Med J. 2012 Jun 20; 102(9):740.
    View in: PubMed
    Score: 0,317
  14. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord. 2009 Apr; 7(2):83-8.
    View in: PubMed
    Score: 0,254
  15. Questioning the importance of LDL cholesterol: don't throw the baby out with the bathwater! Cardiovasc J Afr. 2008 Mar-Apr; 19(2):63-4.
    View in: PubMed
    Score: 0,235
  16. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007 Sep-Oct; 18(5):325-9.
    View in: PubMed
    Score: 0,227
  17. Statins for the prevention of cardiovascular events associated with avian influenza: the COVID-19 pandemic as a reference. Ann Med. 2024 Dec; 56(1):2390166.
    View in: PubMed
    Score: 0,184
  18. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. Lancet Child Adolesc Health. 2024 Jul; 8(7):491-499.
    View in: PubMed
    Score: 0,181
  19. Heart groups in South Africa advocate for tighter LDL-C control and lipoprotein(a) testing to curb atherosclerotic cardiovascular disease. S Afr Med J. 2024 May 09; 114(5):e1973.
    View in: PubMed
    Score: 0,181
  20. Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention. Atherosclerosis. 2024 Apr; 391:117472.
    View in: PubMed
    Score: 0,178
  21. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 01 07; 44(2):129-138.
    View in: PubMed
    Score: 0,165
  22. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther. 2024 Jun; 38(3):493-503.
    View in: PubMed
    Score: 0,164
  23. Non-HDL-C and LDL-C/HDL-C are associated with self-reported cardiovascular disease in a rural West African population: Analysis of an array of lipid metrics in an AWI-Gen sub-study. PLoS One. 2022; 17(12):e0278375.
    View in: PubMed
    Score: 0,164
  24. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020 06 21; 41(24):2313-2330.
    View in: PubMed
    Score: 0,138
  25. PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. Endocr Metab Immune Disord Drug Targets. 2020; 20(6):840-854.
    View in: PubMed
    Score: 0,134
  26. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 03 15; 19(1):61.
    View in: PubMed
    Score: 0,126
  27. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovasc J Afr. 2019 Jan/Feb 23; 30(1):15-23.
    View in: PubMed
    Score: 0,125
  28. South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J. 2018 10 26; 108(11b):973-1000.
    View in: PubMed
    Score: 0,123
  29. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol. 2017 11; 24(17):1843-1850.
    View in: PubMed
    Score: 0,114
  30. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016 10; 4(10):850-61.
    View in: PubMed
    Score: 0,104
  31. Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol. 2015 Nov; 35(11):2269-80.
    View in: PubMed
    Score: 0,099
  32. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1489-99.
    View in: PubMed
    Score: 0,096
  33. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.
    View in: PubMed
    Score: 0,096
  34. Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. PLoS One. 2014; 9(8):e102830.
    View in: PubMed
    Score: 0,092
  35. Targeting LDL: is lower better and is it safe? Best Pract Res Clin Endocrinol Metab. 2014 Jun; 28(3):309-24.
    View in: PubMed
    Score: 0,087
  36. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012 Aug; 223(2):262-8.
    View in: PubMed
    Score: 0,077
  37. The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). Cardiovasc J Afr. 2008 Mar-Apr; 19(2):88-94.
    View in: PubMed
    Score: 0,059
  38. Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry. Eur Heart J. 2025 Mar 24; 46(12):1127-1140.
    View in: PubMed
    Score: 0,048
  39. Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2024 Dec 14; 404(10470):2462-2475.
    View in: PubMed
    Score: 0,047
  40. Does Engagement in HIV Care Affect Screening, Diagnosis, and Control of Noncommunicable Diseases in Sub-Saharan Africa? A Systematic Review and Meta-analysis. AIDS Behav. 2024 Feb; 28(2):591-608.
    View in: PubMed
    Score: 0,044
  41. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 04 16; 382(16):1507-1519.
    View in: PubMed
    Score: 0,034
  42. Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Curr Atheroscler Rep. 2019 11 19; 21(12):48.
    View in: PubMed
    Score: 0,033
  43. Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 1995 Mar; 113(2):289-92.
    View in: PubMed
    Score: 0,024
  44. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):689-99.
    View in: PubMed
    Score: 0,024
  45. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21; 35(32):2146-57.
    View in: PubMed
    Score: 0,023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.